Indee Labs
Enabling T cell immunotherapy and manufacturing through non-viral gene delivery.
Enabling T cell immunotherapy and manufacturing through non-viral gene delivery.
Indee Labs is a biotechnology startup that is focused on enabling T cell immunotherapy and manufacturing through non-viral gene delivery. Founded in 2015, the company has garnered support from prominent investors including SOSV, Y Combinator, Social Capital, Founders Fund, and most recently BioTools Innovator with a Non-Equity Assistance investment on June 6, 2023.
Their flagship product, Hydropore, offers a non-viral delivery platform that addresses the limitations and costs associated with other methods such as electroporation and viral transduction. Indee Labs has established collaborations with 3 of the top 10 pharmaceutical companies, various biotechs, and prestigious research institutions including UC San Francisco, Stanford, Medical University of South Carolina, the National Cancer Institute, and the National Institute of Allergy and Infectious Disease.
With a focus on biotechnology and manufacturing, Indee Labs is positioned at the forefront of engineered cell therapies, seeking to enhance their effectiveness. Based in the United States, the company's innovative approach and strategic partnerships underscore its potential for meaningful contributions to the field of biotechnology and healthcare.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Non Equity Assistance | Unknown | 1 |
|
06 Jun 2023 |
| Convertible Note | Unknown | 2 |
|
23 Sep 2021 |
| Seed Round | Unknown | 2 |
|
02 Nov 2020 |
| Grant | Unknown | 1 | National Institute of Allergy and Infectious Diseases | 24 Aug 2020 |
| Grant | $500.00K | 1 | NSW Medical Devices Fund | 10 Aug 2018 |
No recent news or press coverage available for Indee Labs.
We care about your data, and we'd love to use cookies make your experience better.
